When the ACR Convergence 2024 abstract site went live, the first query I typed into the search bar was, “CAR-T.” I consider myself a CAR-T skeptic and would be surprised if the magical results from this NEJM case series replicate at scale, but it seems likely that CAR-T will revolutionize the care for (some) patients with rheumatic diseases. What new data will be presented at ACR?
All News
Article
Article
Are emulation ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?
Article
Studies show that patients with difficult-to-manage axSpA have a higher disease activity; however, the lack of a consensus definition led researchers and clinicians to utilize their own proposed definition, resulting in variability of the characteristics of non-responders.
Brian Jaros, MD
Tweet
New agent on the block: Bimekizumab IL-17A/F inhibitor
Promising clinical data in SpA - what about imaging findings?
Dramatic reductions in MRI activity at SI joints seen in BKZ pt, esp when compared to trajectory of PBO pt before cross-over
@RheumNow #ACR24 Abst #1757 https://t.co/ACLJx5XkyN
Eric Dein
Tweet
Appreciate the conversation with Dr Ana-Maria Orbai @jhrheumatology on abstract#0600 on bimekizumab PRO data
https://t.co/86J4HWKeIv
@RheumNow #ACR24 https://t.co/QYqj5rKHIH
sheila
Tweet
GILZ is a negative regulator of the GC receptor, a potential steroid sparer target.
Dr. Miceli et al identified an E3 ligase of GILZ "E3-X" where deficiency leads to ⬆️ GILZ & ⬇️ inflammation.
More studies needed but a promising steroid sparer option.
@Rheumnow #ACR24 abs1646 https://t.co/GuVMkgOTXT
Akhil Sood MD
Tweet
Navigating Positive ANA: Leveraging AI for better triage
Abstract 1526: Markus et al. developed a machine learning model to predict progression to SLE, utilizing diagnoses, meds, procedures, and labs collected 2 years before and 5 years after +ANA.
@RheumNow #ACR24 https://t.co/2zzSH8Pb0e
Caoilfhionn Connolly
Tweet
#1474
🔬Severe PsA? Guselkumab (GUS) has promise!
➡️In bionaive pts with severe disease activity,
GUS v. PBO resulted in:
🔴73% improvement in joints
🔴53% lower disease activity
🔴63% better PtGA by 2 years
➡️Rapid results by W2, sustained through W100.
#ACR @RheumNow
Impressive Plenary @andreafava just finished Novel urine protein panel id 12 proteins that predict NIH activity on renal bx better than existing options Improving at 3 mos predicts response at 1 year Could reduce biopsies / modulate tx! #ACR24 @RheumNow Abstr#1642 #ACRbest https://t.co/Gi6u6hAGzj
Antoni Chan MD (Prof)
Tweet
A study presents a novel urinary biomarker panel that predicts histologically active lupus nephritis (LN) with high accuracy.
Key findings:
- AUC of 90% for predicting NIH Activity Index > 2, outperforming traditional biomarkers.
- Identified 12 critical proteins linked to… https://t.co/6ZhqNaxpQM
Phase 2 DBRCT of daxdilimab, an immunoglobulin-like transcript 7 to target plasmacytoid dendritic cells
No difference in primary outcome... but kiiiinda looks like something there?
I dislike Phase 2's; should go straight to Phase 3 if able
#ACR24 @rheumnow Abstr#1542 https://t.co/osDWDskfnA
sheila
Tweet
Systematic review & meta-analysis by DrHChaudhary et al @DaoudAnsaam @mmagrey1
showed that males w/ axSpA who were treated with biologics had ⬆️ BASDAI150 response & likely w/ ASDAS low dse activity vs. females w/axSpA
Again, effect of gender differences
@RheumNow #ACR24 abs599 https://t.co/2DPYC8exES
Richard Conway
Tweet
Coming from somewhere where biosimilars are SOC for many years, I just find it wild how things are biosimilar wise in the US. Reflected by so many abstracts, including lots of oral presentations, essentially on showing biosimilars work. #ACR24 @RheumNow
How does #cardiovascular risk vary with #ACPA & #biologics in #RA?
⬆️BMI assoc with ⬆️MACE risk in ACPA+ pts
In ACPA- pts, BMI inversely assoc with MACE risk among pts on biologics
Further evidence to consider ACPA, BMI & MACE as part of RA management
Ab0870 #ACR24 @RheumNow https://t.co/UkkC146DWS
Richard Conway
Tweet
Stone et al. Phase 3 RCT B-cell depletion with CD19 targeting agent Inebilizumab in IgG4-RD. HR 0.13 (0.06, 0.28) for flare. @RheumNow #ACR24 Abstr#0775 https://t.co/Kd4Xmoc5e6 https://t.co/Al6gOA1F8K
Medication-assisted weight loss has boomed in recent yrs. How does weight loss affect disease activity & PROs in RMDs?
≥5% weight loss, after taking a med, led to better disease activity & QoL
Data may inform RCTs to explore effect of these meds in RMDs
Ab0845 #ACR24 @RheumNow
Results from MANDARA- #EGPA pts treated with benralizumab or mepolizumab
Eosinophil-targeting biologics rapidly control airway- & non-airway-related manifestations
Few pts had worsening of disease that progressed to organ damage over 52W
Ab0828 #ACR24 @RheumNow https://t.co/hIn9iyNVWQ
Eric Dein
Tweet
Ab#0458 #ACR24
10 year outcomes of 176 patients with seroneg RA
32 pts (18%) had change in dx - SpA (11), seropos RA (6), OA (5), crystal (3), CTD (3), Ifn-related/paraneopl/RS3PE, sarcoid (1)
40 (23%) had drug-free remission
30 (17%) started b/tsDMARD
@RheumNow
Richard Conway
Tweet
Langford et al. Abatacept NOT effective in GPA in ABROGATE RCT. 65 patients. Relapse/worsening in 62% vs 68%. No difference in any secondary end-point. @RheumNow #ACR24 Abstr#0823 https://t.co/yRFZ2diJFF https://t.co/LgXkPnDArE
Briefly highlighting this poster, always looking for a non-Georg Schett CAR-T study to see if their results replicate
All 10 pts in this one had a "complete humoral response," normalizing antibodies & experiencing long term drug-free remission
#ACR24 @RheumNow Abstr#0673 https://t.co/pjOjRnJVhO
